The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication

Blood

Volumn 114, Issue 20, 2009, Pages 4601-4602

  Micol, Jean Baptiste ^a   Boissel, Nicolas ^a   Renneville, Aline ^b   Castaigne, Sylvie ^c   Gardin, Claude ^a   Preudhomme, Claude ^b   Dombret, Hervé ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CHROMOSOME ABERRATION; EVENT FREE SURVIVAL; FLT3 GENE; GENE; GENE MUTATION; GENOTYPE; HUMAN; KARYOTYPE; LETTER; NPM1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; ADOLESCENT; ADULT; AGED; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; NOTE; NUCLEOTIDE SEQUENCE; SURVIVAL; TANDEM REPEAT;

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 73349093723     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230995     Document Type: Letter

References (8)

1. Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biological, pathological, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024-3032.
2. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
3. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467-2474.
4. Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453-461.
5. Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML patients aged 50 to 70 and of maintenance with interleukin-2: final analysis of the ALFA 9801 study [abstract]. Blood. 2007;110:162a.
6. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16(9):1699-1704.
7. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106(10):3618-3620.
8. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood. 2009;113(21):5090-5093.